Announcements
Sidley Represents Shinobi Therapeutics in its Series A Financing
December 13, 2023
Sidley represented Shinobi Therapeutics, a biotechnology company developing a new class of immune-evasive iPS-T cell therapies, in its US$51 million Series A financing. The round was led by EQT Life Sciences, F-Prime Capital, and Eight Roads Ventures Japan, with participation from Astellas Venture Management, Fast Track Initiative, JIC Venture Growth Investments, and D3 LLC.
Additional information about the transaction can be found here.
The Sidley team was led by partners Asher Rubin (Technology and Life Sciences Transactions)
and Alison Lehner (Emerging Companies and Venture Capital) with support from Shaika Ahmed and Yahel Kaplan (Emerging Companies and Venture Capital), as well as Idan Netser and Alvin Wang (Tax).
Additional information about the transaction can be found here.
The Sidley team was led by partners Asher Rubin (Technology and Life Sciences Transactions)
and Alison Lehner (Emerging Companies and Venture Capital) with support from Shaika Ahmed and Yahel Kaplan (Emerging Companies and Venture Capital), as well as Idan Netser and Alvin Wang (Tax).
Contacts
Baltimore
+1 410 559 2881Baltimore
2850 Quarry Lake Drive, Suite 301
Baltimore, MD 21209
Baltimore
+1 410 559 2884Baltimore
2850 Quarry Lake Drive, Suite 301
Baltimore, MD 21209
Offices
Capabilities
Suggested News & Insights
Sidley Represents Immunovant in US$550 Million OfferingDecember 12, 2025Sidley Ranked in Chambers Asia-Pacific 2026December 11, 2025Sidley Represents JOLT in its Agreement to Acquire Assets from Volta Media NetworkDecember 10, 2025Sidley Represents Jane Street in Investments in Kraken and X-EnergyDecember 3, 2025Sidley Represents Nuvalent in Pricing of US$500 Million Public OfferingNovember 20, 2025Sidley Represents RA Capital Management in Artios Pharma’s US$115 million Series D FundingNovember 20, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory